Nikolai Kley

Company: Orionis Biosciences LLC

Job title: Founder & Chief Executive Officer

Seminars:

Using Modified Cytokines to Target Immune Receptors for Selective Response Towards Cancer 5:15 pm

Designing modified cytokines that have low affinity/activity towards their natural receptors How to use induced proximity to restore/drive interactions between the modified cytokine and its natural receptor(s) Optimizing selectivity/pharmacology of the modified cytokine by focusing on localizing activity to clinically relevant targets for alleviating diseaseRead more

day: Conference Day One